RGLS Regulus Therapeutics Inc. Stock Quote

RGLS [NASD]

Index	-	P/E	-	EPS (ttm)	-0.39	Insider Own	0.50%	Shs Outstand	71.29M	Perf Week	-1.16%
Market Cap	54.92M	Forward P/E	-	EPS next Y	-0.34	Insider Trans	-2.57%	Shs Float	71.22M	Perf Month	-28.72%
Income	-15.80M	PEG	-	EPS next Q	-0.08	Inst Own	49.80%	Short Float	8.71%	Perf Quarter	-50.97%
Sales	10.00M	P/S	5.49	EPS this Y	58.20%	Inst Trans	0.29%	Short Ratio	1.88	Perf Half Y	-45.64%
Book/sh	0.38	P/B	1.85	EPS next Y	-3.00%	ROA	-47.00%	Target Price	1.17	Perf Year	-11.06%
Cash/sh	0.40	P/C	1.74	EPS next 5Y	39.60%	ROE	-91.00%	52W Range	0.42 - 2.32	Perf YTD	-48.06%
Dividend	-	P/FCF	-	EPS past 5Y	49.00%	ROI	-46.10%	52W High	-69.78%	Beta	2.21
Dividend %	-	Quick Ratio	3.70	Sales past 5Y	-13.60%	Gross Margin	-	52W Low	66.08%	ATR	0.06
Employees	23	Current Ratio	3.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	35.08	Volatility	5.98% 6.80%
Optionable	Yes	Debt/Eq	0.17	EPS Q/Q	65.80%	Profit Margin	-	Rel Volume	0.22	Prev Close	0.73
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 13 AMC	Payout	-	Avg Volume	3.30M	Price	0.70
Recom	2.70	SMA20	-10.34%	SMA50	-22.93%	SMA200	-35.42%	Volume	727,567	Change	-4.27%

Mar-28-18

Initiated

B. Riley FBR, Inc.

Neutral

Jan-05-18

Initiated

Leerink Partners

Outperform

Jun-13-17

Reiterated

Chardan Capital Markets

Buy

$5 → $2.50

Mar-06-17

Reiterated

Wedbush

Outperform

$8 → $6

Jan-30-17

Downgrade

Wells Fargo

Outperform → Market Perform

Jan-30-17

Downgrade

Needham

Buy → Hold

Dec-07-16

Reiterated

Chardan Capital Markets

Buy

$12 → $5

Nov-02-16

Reiterated

Needham

Buy

$10 → $9

Jul-25-16

Reiterated

Chardan Capital Markets

Buy

$14.50 → $12

Jun-28-16

Reiterated

Needham

Buy

$25 → $10

Jun-28-16

Reiterated

FBR Capital

Outperform

$30 → $9

Jun-28-16

Reiterated

Chardan Capital Markets

Buy

$20 → $13.50

Jun-07-16

Reiterated

Chardan Capital Markets

Buy

$15 → $20

Apr-13-16

Initiated

Chardan Capital Markets

Buy

$15

Dec-04-15

Initiated

Wells Fargo

Outperform

Jun-09-15

Initiated

Guggenheim

Buy

Apr-21-15

Resumed

FBR Capital

Outperform

$30

Nov-24-14

Initiated

Deutsche Bank

Buy

$30

Aug-07-14

Reiterated

FBR Capital

Outperform

$14 → $15

Aug-14-13

Reiterated

Needham

Buy

$8 → $12

Jun-30-21 09:33AM	Is Regulus Therapeutics Inc (RGLS) A Good Stock To Buy? Insider Monkey
Jun-25-21 01:38PM	Regulus Therapeutics Presents Additional Data From Rare Kidney Disease Program Benzinga -8.50%
07:05AM	Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 PR Newswire
Jun-21-21 07:00AM	Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 PR Newswire +13.20%
Jun-11-21 08:56AM	Do Options Traders Know Something About Regulus Therapeutics (RGLS) Stock We Don't? Zacks
May-21-21 10:47AM	Regulus's Polycystic Kidney Disease Candidate Shows Benefit At Interim Analysis Benzinga
08:07AM	Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program PR Newswire
May-14-21 04:07PM	Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit PR Newswire +7.32%
May-13-21 05:35PM	Regulus (RGLS) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:07PM	Regulus Therapeutics Reports First Quarter 2021 Financial Results and Recent Updates PR Newswire
03:15PM	Regulus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-06-21 03:01PM	Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks -8.74%
May-03-21 09:25AM	Regulus Therapeutics' RGLS4326 Reports Mixed Bag On Polycystic Kidney Disease-Associated Biomarker Study Benzinga -19.42%
08:00AM	Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire
Apr-15-21 08:07AM	Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire
Apr-07-21 08:07AM	Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference PR Newswire
Mar-10-21 04:03AM	Investors Who Bought Regulus Therapeutics (NASDAQ:RGLS) Shares A Year Ago Are Now Up 101% Simply Wall St.
Mar-09-21 04:07PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates PR Newswire +7.03%
Mar-05-21 04:07PM	Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference PR Newswire +13.04%
Mar-04-21 12:30PM	Will Regulus (RGLS) Report Negative Q4 Earnings? What You Should Know Zacks -9.45%
Feb-10-21 08:07AM	Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire
Jan-27-21 08:07AM	Regulus Announces Addition to Board of Directors PR Newswire -10.32%
Jan-05-21 08:07AM	Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference PR Newswire
Dec-09-20 08:54AM	Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock? Zacks
Dec-08-20 08:07AM	Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity PR Newswire +15.19%
Dec-02-20 07:00AM	Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development PR Newswire
Dec-01-20 08:35AM	Regulus Therapeutics Announces Private Placement of Equity PR Newswire +11.09%
Nov-29-20 02:33PM	Should I Buy Regulus Therapeutics Inc (RGLS)? Insider Monkey
Nov-05-20 05:25PM	Regulus (RGLS) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:07PM	Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates PR Newswire
Nov-03-20 12:31PM	Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Nov-02-20 08:07AM	Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with Sanofi PR Newswire
Oct-15-20 08:07AM	Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire
Oct-13-20 08:07AM	Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi PR Newswire +8.38%
Sep-11-20 08:07AM	Regulus Therapeutics to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference PR Newswire
Sep-08-20 08:28AM	What You Need To Know About The Regulus Therapeutics Inc. (NASDAQ:RGLS) Analyst Downgrade Today Simply Wall St.
Sep-03-20 08:07AM	Regulus Therapeutics to Present at the 2020 Wells Fargo Virtual Healthcare Conference PR Newswire
Aug-31-20 08:07AM	Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements PR Newswire -7.00%
Aug-13-20 06:05PM	Regulus (RGLS) Reports Q2 Loss, Lags Revenue Estimates Zacks -6.10%
04:07PM	Regulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent Updates PR Newswire
Aug-06-20 12:30PM	Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -6.40%
08:07AM	Regulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference PR Newswire
Aug-03-20 08:07AM	Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer PR Newswire
Jul-29-20 08:07AM	Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire +5.22%
Jul-22-20 08:07AM	Regulus Therapeutics Completes Dosing in Phase 1 Multiple Ascending Dose Study of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire -11.58%
Jun-12-20 08:01AM	Analysts' Revenue Estimates For Regulus Therapeutics Inc. (NASDAQ:RGLS) Are Surging Higher Simply Wall St. +10.47%
May-14-20 04:07PM	Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates PR Newswire
May-07-20 12:30PM	Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Mar-12-20 04:37PM	Regulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent Updates PR Newswire -13.54%
Mar-09-20 12:30PM	Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
Feb-13-20 04:30PM	Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD PR Newswire
Jan-21-20 07:47AM	How Regulus Therapeutics Inc. (NASDAQ:RGLS) Can Impact Your Portfolio Volatility Simply Wall St. +8.26%
Dec-22-19 07:44PM	Hedge Funds Are Dumping Regulus Therapeutics Inc (RGLS) Insider Monkey
Dec-16-19 08:00AM	Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326 PR Newswire -6.78%
Nov-18-19 08:07AM	Regulus Therapeutics to Present at the Stifel Healthcare Conference PR Newswire
Nov-15-19 01:37PM	Analysts Are Upgrading Regulus Therapeutics Inc. After Its Latest Results Simply Wall St. -5.78%
Nov-12-19 05:55PM	Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:05PM	Regulus Therapeutics Reports Third Quarter 2019 Financial Results and Recent Updates PR Newswire
Nov-07-19 10:30AM	Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-16-19 04:15PM	Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting PR Newswire
Sep-20-19 01:30PM	Some Regulus Therapeutics (NASDAQ:RGLS) Shareholders Have Copped A 99% Share Price Wipe Out Simply Wall St.
Sep-12-19 08:00AM	Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD PR Newswire +5.26%
Sep-03-19 04:10PM	Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference PR Newswire +8.87%
Aug-29-19 04:10PM	Regulus Therapeutics to Present at the Wells Fargo Healthcare Conference PR Newswire
Aug-08-19 07:20PM	Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:10PM	Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates PR Newswire
Aug-06-19 02:50PM	What Percentage Of Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Do Insiders Own? Simply Wall St.
Aug-01-19 10:33AM	Will Regulus (RGLS) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-30-19 08:00AM	Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer PR Newswire -11.47%
Jul-29-19 11:33AM	Penny Stocks to Buy Using Technical Analysis for August 2019 Investopedia
Jul-23-19 06:30PM	Regulus Therapeutics Announces RGLS4326 Program Update PR Newswire
Jun-11-19 05:00AM	Regulus Announces New Additions to Board of Directors PR Newswire
May-10-19 05:39AM	Regulus: 1Q Earnings Snapshot Associated Press +6.40%
May-09-19 04:05PM	Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates PR Newswire
May-07-19 04:05PM	Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity PR Newswire
May-06-19 09:15AM	Regulus Therapeutics Announces Restructuring of Term Loan PR Newswire +16.67%
09:00AM	Regulus Therapeutics Announces Private Placement of Equity PR Newswire
May-02-19 10:32AM	Will Regulus (RGLS) Report Negative Q1 Earnings? What You Should Know Zacks -5.20%
Apr-08-19 08:00AM	Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress 2019 PR Newswire
Mar-28-19 09:45AM	Four Healthcare Stocks Getting a Boost on Thursday ACCESSWIRE -6.36%
Mar-18-19 08:53AM	Regulus: 4Q Earnings Snapshot Associated Press
08:00AM	Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates PR Newswire
Mar-15-19 06:00PM	Regulus Announces Transition of Research Leadership PR Newswire -19.86%
Jan-07-19 08:00AM	Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme PR Newswire
Jan-04-19 04:05PM	Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study PR Newswire +11.11%
Dec-20-18 09:56AM	Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares Simply Wall St.
Nov-28-18 07:35AM	Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +6.00%
Nov-19-18 08:00AM	Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme PR Newswire
Nov-08-18 06:40PM	Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates Zacks
05:38PM	Regulus: 3Q Earnings Snapshot Associated Press
04:05PM	Regulus Reports Third Quarter 2018 Financial Results and Recent Updates PR Newswire
Nov-06-18 07:30AM	Regulus Announces Successful Restructuring of Sanofi Collaboration PR Newswire +6.38%
Oct-25-18 04:05PM	Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018 PR Newswire
Oct-23-18 11:30AM	3 Healthcare Stocks To Watch On Tuesday ACCESSWIRE +15.85%
08:35AM	The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares Benzinga
Oct-22-18 04:05PM	Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018 PR Newswire
Oct-18-18 04:05PM	Regulus Regains Compliance with NASDAQ Listing Requirements PR Newswire
Oct-17-18 07:45AM	Research Report Identifies Oxford Immunotec Global, Ascena Retail Group, Groupon, Epizyme, Regulus Therapeutics, and B Communications with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-04-18 08:05AM	Regulus Therapeutics Announces Reverse Stock Split PR Newswire
Oct-02-18 04:05PM	Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference PR Newswire

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hagan Joseph P	President and CEO	May 17	Sale	0.89	4,186	3,726	316,292	May 17 07:13 PM
Aker Christopher Ray	Sr. VP & General Counsel	May 17	Sale	0.89	860	765	41,754	May 17 07:12 PM
Aker Christopher Ray	Sr. VP & General Counsel	Feb 16	Sale	1.72	828	1,424	42,614	Feb 17 05:23 PM
Hagan Joseph P	President and CEO	Feb 16	Sale	1.72	4,144	7,128	485,756	Feb 17 05:23 PM
Sonsini Peter W.	10% Owner	Dec 04	Buy	0.62	4,398,602	2,735,930	6,451,056	Dec 07 05:13 PM
Walker Paul Edward	10% Owner	Dec 04	Buy	0.62	4,398,602	2,735,930	6,451,056	Dec 07 05:14 PM
SANDELL SCOTT D	10% Owner	Dec 04	Buy	0.62	4,398,602	2,735,930	6,451,056	Dec 07 05:12 PM
MAKOWER JOSHUA	10% Owner	Dec 04	Buy	0.62	4,398,602	2,735,930	6,451,056	Dec 07 05:12 PM
Florence Anthony A. Jr.	10% Owner	Dec 04	Buy	0.62	4,398,602	2,735,930	6,451,056	Dec 07 05:10 PM
Makhzoumi Mohamad	10% Owner	Dec 04	Buy	0.62	4,398,602	2,735,930	6,451,056	Dec 07 05:11 PM
Chang Carmen	10% Owner	Dec 04	Buy	0.62	4,398,602	2,735,930	6,451,056	Dec 07 05:10 PM
Behbahani Ali	10% Owner	Dec 04	Buy	0.62	4,398,602	2,735,930	6,451,056	Dec 07 05:09 PM
BASKETT FOREST	10% Owner	Dec 04	Buy	0.62	4,398,602	2,735,930	6,451,056	Dec 07 05:08 PM
Growth Equity Opportunities V,	10% Owner	Dec 04	Buy	0.62	4,398,602	2,735,930	6,451,056	Dec 07 05:06 PM
Aker Christopher Ray	Sr. VP & General Counsel	Nov 16	Sale	0.52	876	456	25,762	Nov 18 04:10 PM
Hagan Joseph P	President and CEO	Nov 16	Sale	0.52	6,094	3,176	215,994	Nov 18 04:09 PM
Aker Christopher Ray	Sr. VP & General Counsel	Aug 14	Sale	0.60	872	528	26,638	Aug 17 08:21 PM
Hagan Joseph P	President and CEO	Aug 14	Sale	0.60	4,245	2,568	222,088	Aug 17 08:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience